Die Grünenthal Gruppe

Our Annual Report is fresh off the press! Grünenthal's people have transformed our company over the last few years, uniquely positioning us to meet the increased demand for better pain treatments. 🌎 Our medicines today help more patients than ever before as we are growing our footprint in key pharmaceutical markets, especially in the United States 🧬 We advanced key R&D projects, creating one of the strongest pain-focused pipelines in the industry 📦 We ensured uninterrupted supply of medicines to patients in over 100 countries 💊 Through strategic acquisitions, we expanded our portfolio of established medicines This momentum put us in an excellent position to deliver outstanding business performance.  Read more about our story of transformation in our Annual Report: https://bit.ly/3UklN84 #WeAreGrünenthal #WorldFreeofPain

It is estimated that one in five people suffer from chronic pain. This places a heavy burden on the individual, their family and friends. It also has an impact on the economy and social systems. In Europe alone, the annual cost of chronic pain is in the region of €300 billion. For many of our colleagues, however, chronic pain is not an abstract condition - they have either experienced it themselves or know someone who has and understand what it can mean for those affected.    With a focus on pain treatment and research, we have been dedicated to providing innovative pain medicines for the past 50 years. We continue to work on developing the next generation of treatments to improve the lives of people living with pain. Take a look at our digital company showcase to learn more about our cause: https://bit.ly/4i1TTrh #WeAreGrünenthal #WorldFreeofPain  

One of our highlights in 2024 was the inauguration of a new production facility in Quito, Ecuador: a 1,800-square-metre plant for the production of 300 million tablets annually to serve pain patients across 17 European countries.  Sebastian led the project and has a very special connection to the new facility. In his episode of our series 'Science Made Me', he provides a glimpse into how the new plant was created: https://bit.ly/45jo5X2 #WeAreGrünenthal #WorldFreeofPain

Proud moment for Grünenthal! MSCI Inc. has recognized us as Industry Leader in ESG by awarding us with an ‘AA’ rating. This marks a further external endorsement of our responsibility efforts and highlights our initiatives to attract and retain talent and the strength of our governance practices. How MSCI ESG ratings work: MSCI assesses how well companies manage environmental, social, and governance (ESG) risks and opportunities relative to peers and the industry average. Why it matters: The ‘AA’ rating validates our focus on sustainable growth and reaffirms our commitment to responsible business practices. A huge thank you to our incredible team for helping us achieve this great outcome of our first ever MSCI rating. 🤩 #ESG #Sustainability #WeAreGrünenthal

Donations from our colleagues recently left our headquarters in Aachen to help the people of Ukraine and children across Eastern Europe. Supporting the "Christmas in a Box" campaign, we provide festive surprises for children in orphanages, hospitals and social institutions across Eastern Europe. As part of the Winter Aid for Ukraine💙💛, essentials such as warm clothing, blankets and non-perishable food will help the people of Ukraine get through the coming winter. A big shout out to the colleagues who organised the campaigns and worked with great dedication to make these two initiatives happen again in 2024! #WeAreGrünenthal

On World Diabetes Day, we raise awareness for painful diabetic polyneuropathy, an often overlooked complication of diabetes. Affecting about one in three diabetes patients, polyneuropathy can cause severe pain and significantly impact a patient’s quality of life. Early detection and an accurate diagnosis are crucial for an effective treatment. Listen in as Stephanie Haack, a young diabetes patient, shares her experiences with diabetic polyneuropathy. #WorldDiabetesDay #polyneuropathy #patientvoices #WorldFreeOfPain #WeAreGrünenthal

Our U.S. subsidiary, Averitas Pharma, has completed recruitment for a Phase III clinical trial investigating the efficacy, safety, and tolerability of Qutenza (capsaicin) 8% topical system in post-surgical neuropathic pain. This debilitating complication of surgery occurs after approximately 10% of all surgical procedures and affects more than 3 million people per year in the U.S. The trial is set up to support a respective U.S. label extension, and we expect its topline results in Q4 2025. If the data are positive, we aim to submit a supplemental new drug application for a US label extension in 2026.   When completed, it will be the first blinded randomized controlled trial in post-surgical neuropathic pain that evaluates the long-term treatment effects of a topical neuropathic pain treatment. Read the details in our press release: https://bit.ly/3YTC5qx #WeAreGrünenthal #WorldFreeofPain #ClinicalTrial  

The scale of the flood disaster in Spain has left us deeply saddened and shocked, and our thoughts are with the people who have lost their health, loved ones and belongings.  We have donated €30,000 to the Spanish Red Cross to support the relief efforts on the ground. This donation complements the efforts of our local colleagues from Grünenthal España, who are organising much-needed donations in kind and transporting them to the affected region on their own initiative.  #WeAreGrünenthal

Autumn vibes, warm treats and nice memories! This week, we turned our campus into a cozy, fall-inspired escape with our during our annual Cozy on Campus event. Over four days, we shared a taste of the season with our fantastic teams. It was the perfect blend of work and celebration, from vibrant fall decor to delicious seasonal treats. Here’s to making more cozy memories! 🍂 Check out some impressions of how we embraced the season's spirit together.  #WeAreGrünenthal  

We enrolled the first participants in a first-in-human trial with one of our proprietary nociceptin (NOP) receptor agonists. Building on many years of pioneering research, we aim to deliver a unique and transformative first-in-class treatment option to millions of chronic pain patients. With our candidate, which shows best-in-class selectivity, we aim to solely target the NOP receptor. This may provide robust pain relief in a broad range of chronic pain indications without the serious central nervous system-related side effects associated with opioids. Read the full Press Release through the link in the comments. #WeAreGrünenthal #worldfreeofpain #clinicaltrial